Jump to Navigation

The Latest on Antidepressants

October, 2009 | Vol: 7 Issue: 10

In this issue

Article

Which Antidepressant to Choose?

There is a strange disconnect between what we psychiatrists do in daily practice and what official antidepressant treatment guidelines recommend. Treatment guidelines typically say, essentially, that all antidepressants are equal in efficacy, but real psychiatrists have strong personal preferences, based on some combination of the scientific literature, the advice of experts, our clinical experience, and perhaps even the personalities of the last drug reps we saw in the office. In this article we review a range of evidence to come up with suggestions for which antidepressants to start with, as well as adding bonus material on how to start meds that many of us may have little experience with, namely the tricyclics and the MAOIs.

Pristiq: An Update

Pristiq (desvenlafaxine extendedrelease tablet) was approved by the FDA in February of 2008 for the treatment of major depression. In the April 2008 issue of TCPR, we reviewed the efficacy data available at that time. We concluded that it is a marginally effective antidepressant with no clear advantages over its precursor molecule, venlafaxine extended release (Effexor XR). How has Pristiq fared over the past year and half?

Research Update

Expert QA

Learning Objective

Learning Objectives, Oct. 2009

This CME/CE activity is intended for psychiatrists, psychiatric nurses, psychologists and other health care professionals with an interest in the diagnosis and treatment of psychiatric disorders.

Editorial Information